Mobia Medical Inc (MOBI) Stock Analysis
Verdict: AVOID
Rapid Vivistim adoption and 82.8% gross margins are undercut by an ~8-month cash runway and severe dilution risk near 52-week lows.
Investment score: 37/100
Analysis as of
Is Mobia Medical Inc stock worth reviewing? The TradeMates thesis
Mobia Medical Inc demonstrates rapid revenue scaling and 82.8% gross margins, but severe cash burn ($46.06M FCF loss) and an estimated cash runway of under 9 months generate significant share dilution risk near 52-week lows.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 70/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Mobia Medical Inc opportunities and risks
What speaks for MOBI
- Strong Commercial Revenue Growth
What speaks against MOBI
- Imminent Equity Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MOBI | n/a | 10.8x | n/a | 82.8% | -151.6% | -12.6% |
| CV | n/a | 24.7x | n/a | 50.9% | -214.7% | -8.1% |
| OBIO | n/a | 10.8x | n/a | 99.3% | -184.6% | -17.1% |
| CLPT | n/a | 7.0x | n/a | 62.6% | -81.8% | -10.6% |
| TMCI | n/a | 1.3x | n/a | 79.5% | -29.0% | -9.3% |
| Peer median | n/a | 8.9x | n/a | 71.0% | -133.2% | -10.0% |
Frequently asked questions about Mobia Medical Inc (MOBI)
Is MOBI stock a good investment?
The TradeMates model rates Mobia Medical Inc as AVOID with an investment score of 37/100. Mobia Medical Inc demonstrates rapid revenue scaling and 82.8% gross margins, but severe cash burn ($46.06M FCF loss) and an estimated cash runway of under 9 months generate significant share dilution risk near 52-week lows. This is algorithmic model output, not personal investment advice.
Is MOBI stock a buy?
The TradeMates model verdict for MOBI is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.